The US FDA in a Drug Safety Communication notified healthcare professionals and patients about its ongoing review of data from published studies to evaluate whether use of oral bisphosphonate drugs is associated with an increased risk of cancer of the esophagus. The notification includes: Fosamax (alendronate), Actonel (risedronate), Boniva (ibandronate), Atelvia (risedronate delayed release), Didronel […]

Continue reading about Oral Osteoporosis Drugs (bisphosphonates): Potential Increased Risk of Esophageal Cancer